Abstract: A context-aware voice guidance method is provided that interacts with other voice services of a user device. The voice guidance does not provide audible guidance while the user is making a verbal request to any of the voice-activated services. Instead, the voice guidance transcribes its output on the screen while the verbal requests from the user are received. In some embodiments, the voice guidance only provides a short warning sound to get the user's attention while the user is speaking on a phone call or another voice-activated service is providing audible response to the user's inquires. The voice guidance in some embodiments distinguishes between music that can be ducked and spoken words, for example from an audiobook, that the user wants to pause instead of being skipped. The voice guidance ducks music but pauses spoken words of an audio book in order to provide voice guidance to the user.

Abstract: Systems, devices, and methods for monitoring and assessing blood glucose level in a patient are discussed. An exemplary system receives physiologic information from a patient using an ambulatory medical device. The physiologic information is correlated to, and different from, a direct glucose level measurement. The system determines a glucose index indicative of an abnormal blood glucose level using the received physiologic information by the two or more physiologic sensors. The system may use the glucose index to initiate or adjust a therapy, or to trigger a glucose sensor, separate from the two or more physiologic sensors, to directly measure blood glucose concentration.

Abstract: A user-replaceable e-liquid reservoir for dispensing e-liquid, the reservoir being inserted into, or otherwise attached to, a portable, personal e-cigarette device and engaging with an electrical or electronic pump fluid transfer system in the device, the device including: an electrical or electronic pump, being configured to transfer e-liquid from the e-liquid reservoir to an atomizing unit in the device, the pump delivering a pre-defined or variable quantity of e-liquid from the reservoir; and in which the reservoir is not user-refillable.

Abstract: A liquid formulation of an ophthalmic drug in a pre-filled pharmaceutical package, for example a syringe, cartridge, vial or any other vessel made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. A blister, a pouch, a bag, a tray or a tub may encompass as a secondary packaging the syringe, vial, cartridge, tube or any other vessel. The package is suitable for sterilization (e.g., surface and/or terminal sterilization) with sterilization gas residuals being minimal and/or lower than required by ISO 10993-7; and/or the stability of the ophthalmic drug is maintained, during a prolonged time period following the sterilization. The sterilization gas may be EO, propylene oxide, chlorine dioxide, nitrogen dioxide, or vaporized hydrogen peroxide (VHP), among others.

Abstract: Examples of augmented reality (AR) environment control advantageously employ multi-factor intention determination and include: performing a multi-factor intention determination for summoning a control object (e.g., a menu, a keyboard, or an input panel) using a set of indications in an AR environment, the set of indications comprising a plurality of indications (e.g., two or more of a palm-facing gesture, an eye gaze, a head gaze, and a finger position simultaneously); and based on at least the set of indications indicating a summoning request by a user, displaying the control object in a position proximate to the user in the AR environment (e.g., docked to a hand of the user). Some examples continue displaying the control object while at least one indication remains, and continue displaying the control object during a timer period if one of the indications is lost.

Abstract: A mounting device for an elongate member, comprising: an elongate housing having an elongate axis; an internal passageway passing through the elongate housing parallel to the elongate axis; an elongate sleeve located within the internal passageway and being configured for longitudinal movement along the passageway; a plurality of ball-receiving recesses in the wall of the internal passageway, each recess having a ball-guiding surface inclined to the longitudinal axis; a plurality of apertures in the sleeve; a ball located in each of the ball-receiving recesses and engaged with a respective aperture in the sleeve, the balls and the apertures being configured to allow the balls to project partially through the apertures but to prevent balls from passing through; biasing means configured to bias the sleeve in a direction to urge the balls to project radially inwardly through their respective apertures in the sleeve and into the internal passageway.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: An example welding torch neck adapter includes: an electrically conductive body configured to detachably attach to a handle assembly of a consumable electrode-fed welding torch on a first portion of the conductive body and configured to detachably attach to a neck of the welding torch on a second portion of the conductive body to secure the neck to the handle assembly; and a guide tube positioned within the conductive body and configured to support a first consumable wire liner in alignment with a liner lock of a second consumable wire liner.

Abstract: A liquid formulation of an ophthalmic drug in a pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer.

Abstract: A liquid formulation of an ophthalmic drug in a pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: A vehicle vision system including an isolation block configured to compress under pressure, a rigid block on an interface surface of the isolation block configured to distribute pressure across the interface surface of the isolation block, the rigid block including a first protrusion extending away from the interface surface and having a cavity, and a camera embedded within the cavity and configured to capture video images.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: Various techniques are provided to efficiently detect the position and angular velocity of an object relative to a compact radar system including a transmitter antenna array and a receiver antenna array. In one example, a method includes repeatedly scanning a transmitter antenna array and a receiver antenna array of an object sensing system through a plurality of designated transmitter and receiver channels over a period of time to generate a time series of measured channel responses corresponding to each one of the designated channels, determining a time series of directional vectors to or from an object scanned by at least one of the designated channels, and/or a corresponding time series of average phase differences, based, at least in part, on the time series of measured channel responses, and determining an angular velocity of the object from the time series of directional vectors and/or the corresponding time series of average phase differences.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: An electrostatic painting device capable of reducing any AC or electromagnetic emissions when the device is powered on is provided. The emissions affect electronic components present during painting of various objects or even when the device is powered on. The electromagnetic induction into the conductive circuit elements in turn induces voltages and currents, which potentially harm the micro-electronic circuits. One such device includes a choke between a fluid tip and a high voltage source of the device to reduce these emissions. The voltage source may include at least one capacitor which supplies the AC emissions representing electromagnetic emissions risk during the discharge of paint from the device. The choke connected to the voltage source substantially reduces the emissions involved during the paint discharge, while allowing the discharge of electrons, thereby imparting negative DC charge to the paint and the workpiece, and preventing damage to electronic circuits during the process.

Abstract: An electrostatic painting device capable of reducing any AC or electromagnetic emissions when the device is powered on is provided. The emissions affect electronic components present during painting of various objects or even when the device is powered on. The electromagnetic induction into the conductive circuit elements in turn induces voltages and currents, which potentially harm the micro-electronic circuits. One such device includes a choke between a fluid tip and a high voltage source of the device to reduce these emissions. The voltage source may include at least one capacitor which supplies the AC emissions representing electromagnetic emissions risk during the discharge of paint from the device. The choke connected to the voltage source substantially reduces the emissions involved during the paint discharge, while allowing the discharge of electrons, thereby imparting negative DC charge to the paint and the workpiece, and preventing damage to electronic circuits during the process.

Abstract: Various techniques are provided to efficiently detect the position and angular velocity of an object relative to a compact radar system including a transmitter antenna array and a receiver antenna array. In one example, a method includes repeatedly scanning a transmitter antenna array and a receiver antenna array of an object sensing system through a plurality of designated transmitter and receiver channels over a period of time to generate a time series of measured channel responses corresponding to each one of the designated channels, determining a time series of directional vectors to or from an object scanned by at least one of the designated channels, and/or a corresponding time series of average phase differences, based, at least in part, on the time series of measured channel responses, and determining an angular velocity of the object from the time series of directional vectors and/or the corresponding time series of average phase differences.

Abstract: Various techniques are provided to efficiently detect the position and angular velocity of an object relative to a compact radar system including a transmitter antenna array and a receiver antenna array. In one example, a method includes repeatedly scanning a transmitter antenna array and a receiver antenna array of an object sensing system through a plurality of designated transmitter and receiver channels over a period of time to generate a time series of measured channel responses corresponding to each one of the designated channels, determining a time series of directional vectors to or from an object scanned by at least one of the designated channels, and/or a corresponding time series of average phase differences, based, at least in part, on the time series of measured channel responses, and determining an angular velocity of the object from the time series of directional vectors and/or the corresponding time series of average phase differences.